QMS Medical Allied Services Q1 FY27 Earnings Call Transcript Released
QMS Medical Allied Services reported Q1 FY27 consolidated revenue of ₹56.9 crore (up 22% YoY) and PAT of ₹4 crore (up 25% YoY). EBITDA grew 27% to ₹8.3 crore. The company generated ₹17 crore from PSP services and conducted 11,497 B2B health camps. They are acquiring the remaining stake in Saarathi Healthcare by Q2 FY27 and expect FY27 PSP revenue between ₹90-105 crore.
The announcement details strong financial performance and strategic progress, including increased revenues and improved margins. The acquisition of Saarathi Healthcare and growth initiatives in PSP and Q-Devices are significant but do not represent a fundamental shift that would warrant a 'HIGH' impact.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with improved margins. The successful migration to the NSE main board and strategic progress in PSP and Q-Devices businesses also contribute to a positive sentiment.
QMS Medical Allied Services Limited has released the transcript of their Earnings Conference Call for the quarter ended June 30, 2026, which was held on August 17, 2026. The call featured insights from Chairman and Managing Director Mr. Mahesh Makhija and Director Compliance Mr. Mohit Tamhankar.
During the call, the company reported a strong start to FY27. Consolidated revenues from operations stood at ₹56.9 crore, marking a 22% year-on-year growth. EBITDA grew by 27% to ₹8.3 crore, with an improved EBITDA margin of 14.6%. Profit After Tax (PAT) was around ₹4 crore, a 25% year-on-year increase. Sequentially, revenue increased by 28%, EBITDA by 41%, and PAT more than doubled by 110% over Q4 FY26. The company highlighted the successful migration of its SME platform to the main board of NSE on June 18, 2026.
The company's business operates on two pillars: products and services. The product business saw traction across its healthcare and wellness portfolio, including Q-Devices. The services business, particularly Patient Support Programs (PSP), generated approximately ₹17 crore in revenue in Q1 FY27, with Saarathi Healthcare contributing significantly. QMS Medical Allied Services is progressing towards acquiring the remaining stake in Saarathi Healthcare by the end of Q2 FY27. The company conducted over 11,497 B2B health camps in Q1 FY27.
Looking ahead, the strategy focuses on scaling the service business (especially PSPs), expanding the product business (led by Q-Devices and point-of-care solutions), and leveraging technology across the healthcare ecosystem. The company expects PSP revenue to be around ₹90-95 crore for FY27, with additional contributions potentially bringing it to ₹100-105 crore. The Q-Devices revenue was approximately ₹3 crore in Q1 FY27, with a target of 20-25% contribution to total product revenue in three years. The company maintained its guidance for FY27 top-line at around ₹220 crore and an EBITDA margin of 18%.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.